XACDURO (sulbactam for injection; durlobactam for injection)

XACDURO is a prescription medicine used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). FDA approved Sulbactam/durlobactam (brand name XACDURO) is not (yet) registered or available in India but on request Indian patient can buy XACDURO at the lowest price.

XACDURO (sulbactam/durlobactam) injection Price Delhi India
XACDURO (sulbactam for injection; durlobactam for injection)

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

XACDURO (sulbactam for injection; durlobactam for injection)

Abaloparatide is indicated to treat postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.

XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Sulbactam/durlobactam, sold under the brand name Xacduro (by Innoviva Specialty Therapeutics), is a co-packaged medication used for the treatment of bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex. It contains sulbactam, a beta-lactam antibacterial and beta-lactamase inhibitor; and durlobactam, a beta-lactamase inhibitor.

Sulbactam/durlobactam was approved for medical use in the United States in May 2023.

XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use Initial U.S. Approval: 2023
—————-
Current Indication: Treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
—————-
Marketed By: Entasis Therapeutics Inc.
—————-
Approval Date: : 2023
—————-
Active ingredients: Sulbactam/durlobactam
—————-

XACDURO is a co-packaged kit containing the following two components as sterile powders for reconstitution:
• 1 clear single-dose vial of sulbactam for injection 1 g and
• 2 amber single-dose vials of durlobactam for injection 0.5 g.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.